256 related articles for article (PubMed ID: 26703806)
1. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
Gadgeel SM
Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
[TBL] [Abstract][Full Text] [Related]
2. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
3. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
4. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
5. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
8. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
10. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
13. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
18. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
19. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
20. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]